Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Maze Therapeutics $150 million offering
We advised the sole underwriter on the offering
McKesson sale of minority stake in Medical-Surgical Solutions to Apollo
We are advising McKesson on the transaction
JATT II Acquisition $60 million SPAC IPO
We advised the sole bookrunning manager in connection with the IPO
Revolution Medicines $2.2 billion common stock and convertible notes offerings
We advised the underwriters on the concurrent offerings
Adagene $70 million registered direct offering
We advised Adagene on the offering
AN2 Therapeutics $80 million at-the-market offering
We advised the sales agent on the offering
Carestream Health debt refinancing transaction
We advised an ad hoc group of lenders on the transaction
CytomX Therapeutics $250 million follow-on offering
We advised the representatives of the underwriters on the offering
Novartis $11 billion notes offering
We advised Novartis on the investment-grade debt offering
CRISPR Therapeutics $600 million convertible notes offering
We advised the initial purchasers on the offering